Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo,Kejian Zhang,Wei Lu,Lixin Zheng,Qian Zhang,Chrysi Kanellopoulou,Yu Zhang,Zhiduo Liu,Jill M Fritz,Rebecca Marsh,Ammar Husami,Diane Kissell,Shannon Nortman,Vijaya Chaturvedi,Hilary Haines,Lisa R Young,Jun Mo,Alexandra H Filipovich,Jack J Bleesing,Peter Mustillo,Michael Stephens,Cesar M Rueda,Claire A Chougnet,Kasper Hoebe,Joshua McElwee,Jason D Hughes,Elif Karakoc-Aydiner,Helen F Matthews,Susan Price,Helen C Su,V Koneti Rao,Michael J Lenardo,Michael B Jordan,Jill M. Fritz,Lisa R. Young,Alexandra H. Filipovich,Jack J. Bleesing,Cesar M. Rueda,Claire A. Chougnet,Jason D. Hughes,Helen F. Matthews,Helen C. Su,V. Koneti Rao,Michael J. Lenardo,Michael B. Jordan
DOI: https://doi.org/10.1126/science.aaa1663
IF: 56.9
2015-07-24
Science
Abstract:Trafficking from bedside to bench Typically in translational research, a discovery in cell or molecular biology is later exploited to improve patient care. Occasionally, information flows in the opposite direction. Lo et al. found that patients with an autoimmune disorder caused by deficiency of a protein called LRBA responded dramatically to the drug abatacept (see the Perspective by Sansom). Abatacept contains a segment of a potent inhibitory immune receptor, CTLA4. Experiments prompted by this observation revealed the relationship between the two proteins: LRBA controls the intracellular trafficking and degradation of CTLA4. This information may further improve patient care, because other clinically approved drugs have the desired mechanism of action with potentially fewer side effects. Science , this issue p. 436 ; see also p. 377
multidisciplinary sciences